Table 2.
Glycemic variability at baseline and after three months.
| Ranolazine | No ranolazine | |||||
|---|---|---|---|---|---|---|
| Baseline | 3 months | p value | Baseline | 3 months | p value | |
| FPG (mg/dl) | 121 ± 36 | 102 ± 14 | 0.072 | 131 ± 61 | 119 ± 28∗ | 0.460 |
| Hb1Ac (%) | 7.2 ± 0.7 | 6.6 ± 0.5 | <0.001 | 7.6 ± 1.2 | 7.5 ± 1.1∗ | 0.928 |
| TIR (%) | 61 (46, 74) | 78 (73, 96) | 0.001 | 51 (28, 71) | 62(15, 77)∗ | 0.408 |
| TBR (%) | 0 (0, 13) | 0 (0, 0) | 0.116 | 0 (0, 9) | 0.5 (0.5, 10) | 0.929 |
| TAR (%) | 28 (10, 42) | 16 (4, 26) | 0.010 | 40 (24, 67) | 33 (10, 85) | 0.277 |
| SD (mg/dl) | 32.7 ± 11.1 | 25.3 ± 9.2 | 0.023 | 37.3 ± 13.0 | 33.0 ± 14.7 | 0.269 |
| CV (%) | 28.0 ± 9.0 | 21.2 ± 8.3 | 0.020 | 27.6 ± 10.8 | 23.8 ± 7.4 | 0.186 |
| MAGE (mg/dl) | 56.8 ± 23.6 | 44.8 ± 18.1 | 0.042 | 56.3 ± 18.1 | 58.8 ± 17.2∗ | 0.653 |
∗ p < 0.05 compared with 3-month results in the ranolazine cohort; values are mean ± SD or median(Q1, Q3). CV: coefficient of variation; FPG: fasting plasma glucose; HbA1c: haemoglobin A1c; MAGE: mean amplitude glycemic excursions; SD: standard deviation; TAR: time above range; TBR: time below range; TIR: time in range.